GET DAILY SIGNALSIRIDEX (IRIX) Stock Drops -19% in 30 Days: Analyzing the Recent Pullback
Key Takeaways
- IRIDEX shares fell roughly 19% over the trailing 30 days, from about $0.82 on October 14, 2026, to approximately $0.67 by November 13, 2026.
- The decline reflects a sharp retracement after an early-October surge, rather than a single negative company announcement.
- An October 12 clinical study supporting MicroPulse technology, an insider purchase, and a manufacturing relocation helped fuel the earlier spike that later faded.
- Over the trailing quarter, the stock is down roughly 12%, underscoring a broader multi-month downtrend.
- Second-quarter results missed revenue and earnings estimates, and the company reaffirmed 2026 revenue guidance of $51 million to $53 million.
- Third-quarter 2026 results are scheduled to be released after the close on November 17, 2026, a key near-term catalyst.
- Explore additional details on Price Targets, Earnings, and Forecast for a fuller view of IRIX.
- For automated, data-driven ideas, explore Trending AI Robots.
A Quick Look at IRIDEX and Its Market Position
IRIDEX Corporation develops, manufactures, and markets laser-based medical systems and related devices for treating glaucoma and retinal diseases. Its MicroPulse technology stands out for delivering precise therapy with less tissue impact, and the company focuses on non-incisional options. Key offerings include the Cyclo G6 system, IQ 532 and IQ 577 lasers, the PASCAL pattern-scanning platform, and single-use probes. Sales reach the U.S. directly and more than 100 countries via distributors. As a micro-cap player with recurring probe revenue and an installed base in retina procedures, IRIX draws attention from investors tracking medical-device trends, reimbursement shifts, and the path to sustained profitability.
IRIX Price Action Over the Past 30 Days and Quarter
In the last 30 days, IRIX declined about 19%, moving from a close near $0.82 on October 14, 2026, to roughly $0.67 on November 13, 2026. The path was not straight—the stock briefly traded above $1.00 intraday in early October before giving ground. Over the trailing quarter the drop stands at around 12%, showing pressure that predates the October move. Volatility has stayed elevated on modest volume, which is common for smaller names where sentiment shifts can amplify percentage changes. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Drivers Behind the Recent 30-Day Move
October events set the tone. On October 5 the company completed its manufacturing shift to San Jose, California, with expected annual savings near $600,000. An insider filing soon after showed a purchase of about $438,762 in shares. On October 12 a two-year independent study highlighted benefits of MicroPulse technology for glaucoma patients across disease stages, including lasting pressure reduction. These elements supported a short rally. Momentum faded without fresh positive news and limited liquidity. On November 3 the firm set its third-quarter 2026 earnings date, turning attention to the upcoming report and the chance of another revenue shortfall after the second quarter missed estimates.
Quarterly Performance Context
Second-quarter 2026 revenue came in at $12.57 million versus estimates of $13.59 million, with a loss of $0.07 per share missing the $0.01 consensus. Weaker retina sales and working-capital effects contributed. Management kept full-year revenue guidance at $51 million to $53 million and noted cost-reduction steps tied to the headquarters and manufacturing changes. Glaucoma probe volumes rose 35% year over year, yet retina softness and tariff-related margin pressure weighed on results. The early-October spike stood out against an otherwise downward multi-month trend.
Near-Term Catalysts and Factors to Monitor
The third-quarter 2026 earnings release on November 17, 2026, will be the next focal point, with attention on revenue trends, gross margins, cash flow, and any guidance updates. Other items include Cyclo G6 probe adoption in the U.S., progress on European regulatory clearances for PASCAL, and effects from the Medicare coverage determination supporting laser glaucoma treatments. Cost savings from the relocation, tariff impacts, and the cash position will also matter. Liquidity and volatility remain key considerations for this micro-cap name. I’m watching this closely as the earnings date approaches.
Exploring AI Tools for Additional Perspective
I find it helpful to supplement fundamental work on names like IRIX with systematic tools. Tickeron’s Trending AI Robots page highlights top-performing automated strategies from a larger set of bots that follow thousands of tickers. Each robot brings its own timeframe and risk approach, allowing investors to compare options and see which signals might fit their goals. The section provides a focused way to explore data-driven ideas alongside traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
IRIX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 06, 2026
IRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 42 of 49 cases where IRIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +1.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in 151 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The 10-day RSI Indicator for IRIX moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRIX as a result. In 79 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for IRIX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 31 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
IRIX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IRIX crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for IRIX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.955) is normal, around the industry mean (4.142). P/E Ratio (-3.330) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (3.870) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.204) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. IRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of light-based medical systems and delivery devices
Industry MedicalNursingServices
Advertisement